Respiratory Diseases - Lung cancer cells activate different signaling pathways in response to KRAS inhibitors
Can't see this email? View it online
   
  Respiratory Diseases  
  The latest respiratory diseases news from News Medical  
 

#ALT# Apply for your NObreath® FeNO breath monitor today and optimise patient asthma care

The NObreath® FeNO monitor from Bedfont® Scientific Ltd. has been included on the Rapid Uptake Products (RUPs) scheme by the NHS Accelerated Access Collaborative (AAC). One of the potential benefits of being part of the RUP programme is that NHS organisations can apply for a one-off funding from the Pathway Transformation Fund (PTF) to fund adoption through a competitive process.

Find Out More About NObreath®
 
   Lung cancer cells activate different signaling pathways in response to KRAS inhibitorsLung cancer cells activate different signaling pathways in response to KRAS inhibitors
 
Genetic alterations of the KRAS gene are some of the most common mutations in lung cancer patients, but unfortunately these patients have few effective treatment options.
 
   Researchers identify gene variant associated with childhood asthmaResearchers identify gene variant associated with childhood asthma
 
Researchers at Henry Ford Health System, as part of a national asthma collaborative, have identified a gene variant associated with childhood asthma that underscores the importance of including diverse patient populations in research studies.
 
 Scientists generate a detailed molecular atlas of lung development
 
Scientists generate a detailed molecular atlas of lung developmentResearchers at the Perelman School of Medicine at the University of Pennsylvania have produced a detailed molecular atlas of lung development, which is expected to be a fundamental reference in future studies of mammalian biology and of new treatments for diseases, such as COVID-19, that affect the lungs.
 
 
 Chromatin-regulating enzyme found to be a key driver of common lung cancer
 
Chromatin-regulating enzyme found to be a key driver of common lung cancerA chromatin-regulating enzyme has been shown by in-depth interdisciplinary investigations to be a key driver of a common type of lung cancer. Drugs that target the enzyme could improve treatment and survival rates for this particular cancer.
 
 
 Combination therapy produces clinical benefit for early stage non-small cell lung cancer
 
Combination therapy produces clinical benefit for early stage non-small cell lung cancerThe first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.